Wide Ranks

MLYS

Mineralys Therapeutics, Inc.

13.11

Top Statistics
Market Cap 652 M Forward PE -3.49 Revenue Growth 0.00 %
Current Ratio 8.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 263 M Total Cash Per Share 5.30 Total Debt
Total Debt To Equity Current Ratio 8.55 Book Value Per Share 4.76
All Measures
Short Ratio 629.00 % Message Board Id finmb_710468587 Shares Short Prior Month 1 M
Return On Equity -0.6119 City Radnor Uuid 3938497f-b328-3672-a2d9-cbf07921aed8
Previous Close 12.52 First Trade Date Epoch Utc 1 B Book Value 4.76
Volume 93480 Price To Book 2.75 Fifty Two Week Low 6.38
Total Cash Per Share 5.30 Shares Short Previous Month Date 1 B Target Median Price 32.00
Max Age 86400 Recommendation Mean 1.25 Sand P52 Week Change 0.3133
Target Mean Price 32.57 Net Income To Common -153252992 Short Percent Of Float 0.0382
Implied Shares Outstanding 49 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 177880 Average Volume10days 177880 Total Cash 263 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0260 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 12.52
Target Low Price 26.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 13.11
Open 12.56 Free Cashflow -70362872 State PA
Dividend Yield 0.00 % Return On Assets -0.3856 Time Zone Short Name EST
Trailing Eps -3.31 Day Low 12.56 Address1 150 N. Radnor Chester Rd.
Shares Outstanding 49 M Price Hint 2 Target High Price 45.00
Website https://mineralystx.com 52 Week Change 0.9685 Average Volume 162765
Forward Eps -3.47 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 841.60 % Is_sp_500 False Regular Market Day High 13.19
Profit Margins 0.00 % Fifty Two Week High 16.91 Day High 13.19
Shares Short 1 M Regular Market Open 12.56 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0261
Operating Cashflow -128452000 Currency USD Time Zone Full Name America/New_York
Market Cap 652 M Is_nasdaq_100 False Zip 19087
Quote Type EQUITY Industry Biotechnology Long Name Mineralys Therapeutics, Inc.
Regular Market Day Low 12.56 Held Percent Institutions 1.01 Current Price 13.11
Address2 Suite F200 Financial Currency USD Current Ratio 8.55
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 23 M Two Hundred Day Average 12.83 Enterprise Value 388 M
Forward PE -3.49 Regular Market Volume 93480 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.

It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.

The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.